Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11524 posts found.

CHMP recommends treatment for adults with chronic inflammatory disease

June 27, 2022 Sales and Marketing

The CHMP has recommended upadacitinib (RINVOQ® 15 mg, once daily) for approval, for the treatment of adults with active non-radiographic …
News

Monkeypox outbreak in Europe: UK guidance recommends close contacts isolate for 21 days

May 23, 2022 Sales and Marketing

The UK Health Security Agency (UKHSA) has released updated guidance on monkeypox now recommending that those who have had “unprotected …
News

Vaccine for rare but deadly mosquito-borne viruses in clinical trial

May 17, 2022 Sales and Marketing

Positive results for a vaccine for eastern equine encephalitis virus (EEEV), western equine encephalitis virus (WEEV), and Venezuelan equine encephalitis …
News

Eli Lilly’s diabetes treatment wins FDA approval

May 16, 2022 Sales and Marketing

Eli Lilly’s once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide has won FDA approval.The FDA …
News

NHS prescription charges in England to be frozen for first time in 12 years

May 16, 2022 Sales and Marketing

The Department of Health has said that single prescription charges, which normally rise “in line with inflation”, will remain at …
News

Imfimzi for routine use on NHS England for patients with stage III unresectable lung cancer

May 16, 2022 Sales and Marketing

AstraZeneca has announced the NICE recommendation of Imfinzi (durvalumab) for routine use within NHS England as a monotherapy for the …
News

Researchers pinpoint reason for Sudden Infant Deaths

May 16, 2022 Sales and Marketing

Scientists from The Children’s Hospital Westmead in Sydney have discovered that babies who died of sudden infant death syndrome (SIDS) …
News

Evofem’s Phase III trial reveals fewer UTIs in women using Phexxi

May 9, 2022 Sales and Marketing

Evofem has announced new data from the Phase III AMPOWER clinical trial of Phexxi (lactic acid, citric acid, and potassium …
News

FDA places partial clinical hold on BioCryst’s lead candidate, BCX9930

May 9, 2022 Sales and Marketing

The FDA has imposed a partial clinical hold on BioCryst’s Factor D inhibitor, BCX9930. The clinical hold arrives around a …
News

Case of monkeypox confirmed in England

May 9, 2022 Sales and Marketing

The UK Health Security Agency has confirmed that a person in England has been diagnosed with the monkeypox virus.The patient …
News

New data for Shionogi’s COVID-19 antiviral show rapid virus clearance

April 25, 2022 Sales and Marketing

Shionogi has announced new results from two late-breaking presentations of S-217622. This is an investigational 3CL protease inhibitor that was …
News

National shortage of HRT medication due to high demand

April 25, 2022 Sales and Marketing

The national shortage of HRT products could have an impact on some women, who may not be able to sleep …
News

EMA recommend new treatment option for severe postpartum haemorrhage

April 25, 2022 Sales and Marketing

Novo Nordisk has announced that the EMA Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion …
News

Ukraine: crisis for people with chronic diseases

April 25, 2022 Sales and Marketing

Preliminary results from an ongoing nationwide health needs assessment, conducted by WHO in partnership with Premise, indicate that one in …
News

Recipharm announces closing of acquisitions of two major CDMOs

April 11, 2022 Sales and Marketing

Recipharm has announced the closing of its acquisitions of advanced therapy CDMO Arranta Bio and virotherapy CDMO Vibalogics. The acquisitions …
News
The Gateway to Local Adoption Series

Latest content

Siemens Healthineers opens 10m euro R&D centre for laboratory equipment in Ireland

February 19, 2026

Everdrone announces new board of directors to drive expansion

February 19, 2026

Regeneron announces presentations of new data on Eylea HD for retinal disease

February 18, 2026

Indegene completes acquisition of Cake Health

February 18, 2026

Gedeon Richter UK acquires rights to schizophrenia treatment Reagila from Recordati Pharmaceuticals

February 17, 2026